Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Rob who wrote (936)	5/12/1998 10:43:00 AM
From: SAM-DAN	Read Replies (1) \| Respond to of 1501

Don't wish to jeaprodize[sic] my sources[sounds like an anti- Clinton reporter] but one hint- check the Brokerage houses who were buying last couple of days[Rothchild and Goldman-Sachs have favourite houses if they don't want public to know their trades. ]

To: Rob who wrote (936)	5/31/1998 4:24:00 PM
From: Sean Janzen	Read Replies (1) \| Respond to of 1501

Rob, Have you looked at Tularik (http://www.tularik.com). Tularik is a biotech looking for small molecule compounds that inhibit transcription factors such as NF-kB. Tularik has a cancer drug in Phase I but it is still searching for a lead compound for its anti-inflammatory program. A look at Tularik's science. Inflammation Under normal circumstances, inflammation is an important defense response to injury and infection. An early step in the inflammatory response is the recruitment of white blood cells ("leukocytes") from the circulatory system to damaged or infected tissue. Excessive or prolonged accumulation of leukocytes can upset the normal homeostatic balance and lead to pathological inflammatory conditions, including asthma, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis and septic shock. In 1995, a total of approximately 52 million individuals in the U.S., Western Europe and Japan suffered from these inflammatory diseases. The cytokines tumor necrosis factor ("TNF") and interleukin-1 ("IL-1") act by binding to specific cell surface receptors, which in turn set off signaling events culminating in the expression of many inflammatory response genes. The crucial roles played by TNF and IL-1 in several inflammatory disease states have been clearly demonstrated by studies utilizing antibodies and soluble receptors that neutralize TNF and IL-1 activities. These studies suggest that compounds which interfere with TNF or IL-1 action would be effective therapeutics. Tularik scientists have shown that several key inflammatory response genes are regulated by a single transcription factor, NF-kB. These scientists have also discovered numerous novel regulatory proteins in the signal transduction pathways leading from the TNF and IL-1 receptors and have elucidated their roles in NF-kB activation. Tularik scientists are world leaders in this field of research. Based upon this research, Tularik scientists have determined which of these key regulatory proteins appear to be exclusively dedicated to NF-kB activation (and the inflammatory response) and therefore represent ideal drug discovery targets. Five novel assays (three biochemical and two cellular) have been developed and are being utilized to identify potential lead compounds in HTS assays. Tularik believes that its discoveries and the expertise it has developed in this area places it in a unique position to identify the next generation of important anti-inflammatory drugs. Tularik has collaborated with Roche Bioscience in inflammation research since July 1997. Tularik Raises $60 Million in Private Financing Financing Represents Largest Private Placement in Biotech Sector South San Francisco, Calif. -- October 11, 1996 -- Tularik Inc. today announced that investors have committed to purchase in excess of $60 million of Tularik Preferred Stock in a private placement, which the Company believes represents the largest private company financing ever in the biotech sector. September 1997 Tularik announces a $51.25 million private financing. Total equity committed to date: $152 million. October 1997 Tularik acquires Amplicon Corp. and initiates a cancer drug discovery program incorporating Amplicon's genetic analysis technology. Tularik researchers describe in the journal Science the identification of the protein kinase IKK- and evidence for its role in cytokine-induced NF-kB activation, suggesting that it is an attractive target for anti-inflammatory drug discovery.